Sanyo Chemical’s Silk-Elastin, a novel recombinant protein, has demonstrated exceptional efficacy and safety in clinical trials for chronic wound healing. The findings, published in Scientific Reports, confirm its safety and efficacy in accelerating healing and reducing infection risks. With regulatory approval anticipated in Japan, preparations for FDA submission are underway as part of Sanyo Chemical’s plan for U.S. market expansion. To bring this breakthrough treatment to patients as swiftly, Sanyo Chemical is seeking marketing and distribution partners in the U.S.
“The publication in Scientific Reports provides strong scientific validation for Silk-Elastin’s efficacy,” said Akinori Higuchi, President & CEO of Sanyo Chemical. “This groundbreaking material, with its high biocompatibility and resistance to infection, offers a promising new option for chronic wound treatment. With Japan market entry prepared pending regulatory approval, we are actively seeking strategic partners for U.S. expansion. We welcome collaboration with global companies that share our vision for advancing regenerative medicine, particularly through innovative material science.”
Chronic wounds, such as diabetic ulcers and pressure sores, pose significant healthcare challenges worldwide, leading to prolonged suffering and rising medical costs. These wounds often enter a cycle of delayed healing and increased infection risk, making treatment difficult. Current treatments often fail to achieve complete healing. Silk-Elastin offers a regenerative solution, promoting tissue repair while reducing inflammation and bacterial colonization, leading to better patient outcomes and improved quality of life.
Developed in collaboration with Kyoto University, Silk-Elastin has demonstrated remarkable efficacy in both investigator-initiated studies and a multicenter Phase III clinical trial in Japan. Based on these promising results, Sanyo Chemical submitted a regulatory approval application in Japan in April 2024, with approval anticipated. It would become Japan’s first gene-engineered medical device. Sanyo Chemical is now preparing for an FDA submission, marking a key step toward global commercialization.
Reference: https://www.nature.com/articles/s41598-025-88150-w
